<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01472549</url>
  </required_header>
  <id_info>
    <org_study_id>IRB ID #: 201105161</org_study_id>
    <nct_id>NCT01472549</nct_id>
  </id_info>
  <brief_title>The Skin Prep Study</brief_title>
  <official_title>Antiseptic Skin Preparation for Preventing Surgical Site Infection at Cesarean Delivery: a Randomized Comparative Effectiveness Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Washington University School of Medicine</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Washington University School of Medicine</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The investigators propose a randomized controlled clinical trial to determine the comparative&#xD;
      effectiveness of chlorhexidine-alcohol and iodine-alcohol preoperative skin preparation for&#xD;
      preventing surgical site infections at cesarean section. While estimates vary, surgical site&#xD;
      infections complicate up to 5 - 10% of all cesarean sections and result in significant human&#xD;
      suffering and excess health care costs. Interventions such as preoperative antibiotic&#xD;
      prophylaxis reduce surgical site infections by 60%, but the rate of infection remains high.&#xD;
      There is therefore a great need to identify and test other potential interventions to further&#xD;
      reduce these infections.&#xD;
&#xD;
      The skin is a major source of pathogens that cause surgical site infection. Therefore,&#xD;
      optimizing preoperative skin antisepsis has the potential to decrease postoperative surgical&#xD;
      site infections. There is paucity of evidence to guide the choice of antiseptic for skin&#xD;
      preparation at cesarean section. To date, only two underpowered trials have been published&#xD;
      comparing two methods of preoperative skin preparation at cesarean section. A recent&#xD;
      randomized trial in adults undergoing clean-contaminated mostly general surgical procedures&#xD;
      demonstrated a 41% reduction in surgical site infection with the use of chlorhexidine-alcohol&#xD;
      when compared to the more commonly used povidone-iodine. While it is plausible that findings&#xD;
      from trials in other clean-contaminated surgical procedures may apply to cesarean sections,&#xD;
      physiological changes in pregnancy, the peculiar dual microbial source for cesarean-related&#xD;
      infections and the hormone-mediated immune-modulation in pregnancy make the validity of such&#xD;
      extrapolation uncertain.&#xD;
&#xD;
      The study has the following specific aims:&#xD;
&#xD;
      Primary Aim: To test the hypothesis that preoperative chlorhexidine-alcohol skin preparation&#xD;
      at cesarean section significantly reduces surgical site infections compared to&#xD;
      iodine-alcohol.&#xD;
&#xD;
      Secondary Aim 1: To test the hypothesis that preoperative chlorhexidine-alcohol skin&#xD;
      preparation at cesarean section significantly reduces bacterial contamination at the surgical&#xD;
      site compared to iodine-alcohol.&#xD;
&#xD;
      Secondary Aim 2: To determine clinical outcomes and medical costs associated with&#xD;
      cesarean-related infections and quantify potential cost savings attributable to use of&#xD;
      chlorhexidine-alcohol for preoperative skin preparation at cesarean section.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      RESEARCH DESIGN AND METHODS&#xD;
&#xD;
      This will be a randomized controlled clinical trial aimed at determining the comparative&#xD;
      effectiveness of chlorhexidine-alcohol and iodine-alcohol preoperative skin preparation for&#xD;
      preventing surgical site infection at cesarean section.&#xD;
&#xD;
      The investigators will use broad inclusion criteria and analyze all the main outcomes by the&#xD;
      intent-to-treat principle. This approach will allow a more conservative estimate of&#xD;
      differences between groups and allow a better estimate of effectiveness and public health&#xD;
      implications of practice change rather than a pure estimate of efficacy alone.&#xD;
&#xD;
      Randomization and Treatment: Enrolled patients will be randomly assigned in a 1:1 ratio using&#xD;
      computer-generated randomization sequence to the two skin preparation methods.&#xD;
&#xD;
      Blinding: Blinding both patients and physicians to the antiseptic used for skin preparation&#xD;
      (double-blinding) would be ideal. However, it is not feasible in this trial. First, most&#xD;
      patients can determine whether they were assigned to chlorhexidine or iodine, as the two&#xD;
      antiseptics are of different colors and leave a stain on the skin (pink or brown,&#xD;
      respectively). Second, physicians are often in the operating room when the skin is being&#xD;
      prepared for cesarean section and will know which antiseptic is used. We will minimize&#xD;
      systematic bias by using the same standard procedures of skin preparation, skin culture and&#xD;
      assessment of outcomes. All diagnoses of surgical site infection will be verified by chart&#xD;
      review using the Centers for Disease Control and Prevention (CDC) National Nosocomial&#xD;
      Infections Surveillance System criteria. The principal investigator will verify the diagnoses&#xD;
      without knowledge of the group to which the patients were assigned.&#xD;
&#xD;
      PRIMARY AIM:&#xD;
&#xD;
      Outcome measures-Primary outcome-Proportion of subjects with surgical site infection&#xD;
      (superficial incisional [skin, subcutaneous layer] or deep incisional [fascia, muscle])&#xD;
      within 30 days of cesarean delivery. Surgical site infection will be based on diagnosis by&#xD;
      the treating physician and verified by chart review in accordance with the CDC Nosocomial&#xD;
      Infections Surveillance System definitions.&#xD;
&#xD;
      Secondary outcomes-Length of hospital stay, number of office visits and re-admissions for&#xD;
      infection-related complications, endometritis, positive culture from wound culture, skin&#xD;
      irritation and allergic reactions.&#xD;
&#xD;
      Methods-Subjects will undergo cesarean delivery based on the technique selected by the&#xD;
      surgeon. The circulating nurse will record information on key variables known to be related&#xD;
      to surgical site infection: antibiotic administration (type and timing), type of cesarean&#xD;
      section (scheduled or emergent), status of membranes (ruptured or unruptured), duration of&#xD;
      surgery, depth of subcutaneous layer (closed or not closed) and skin closure method&#xD;
      (subcuticular suture or staples) on data collection forms.&#xD;
&#xD;
      Demographic (age, race, socioeconomic status), obstetric (parity, gestational age, indication&#xD;
      for cesarean section, cervical dilation at time of cesarean section, presence of&#xD;
      chorioamnionitis, surgical complications) and neonatal (birth weight, Apgar score, cord pH)&#xD;
      data will be abstracted from the patients chart.&#xD;
&#xD;
      Subjects will be contacted once, up to 30 days from delivery, to assess symptoms of&#xD;
      cesarean-related infections. Patients who report symptoms will be directed to follow up in&#xD;
      the emergency department or with their physician to be evaluated for surgical site infection.&#xD;
      Wound swabs will be taken for aerobic and anaerobic cultures in all subjects who present at&#xD;
      Barnes-Jewish Hospital with wound infection. Medical records will be obtained from treating&#xD;
      physicians to determine the diagnosis at each postoperative office visit or readmission&#xD;
      within 30 days of cesarean section.&#xD;
&#xD;
      Statistical Analysis: Data analyses will be based on the intent-to-treat principle. The&#xD;
      primary outcome (proportion of subjects with surgical site infection) and the other&#xD;
      categorical variables will be compared across groups using the chi-squared test. Fisher's&#xD;
      exact test will be used for variables in which expected numbers in any of the cells in 2 x 2&#xD;
      tables is &lt;5. We will calculate 95% confidence intervals around the differences in&#xD;
      proportions and the relative risk of surgical site infection.&#xD;
&#xD;
      Distribution of continuous variables will be evaluated by visual inspection of histograms and&#xD;
      the Kolmogorov-smirnov test. Normally distributed variables will be compared using the&#xD;
      unpaired t-tests. If variables are not normally distributed, log transformation will be used&#xD;
      in an attempt to achieve normal distribution. If the data is still skewed after log&#xD;
      transformation the Mann-Whitney U test will be used to compare groups.&#xD;
&#xD;
      It is anticipated that baseline characteristics will be similar in the two groups. In the&#xD;
      event that the groups are unbalanced with regards to variables significantly associated with&#xD;
      the primary outcome, supplemental analyses will be performed using stratification on the&#xD;
      individual variables and multivariable logistic regression adjusting for multiple covariates.&#xD;
&#xD;
      Planned subgroup analysis will be performed for: i. scheduled and elective cesarean sections,&#xD;
      iii. obese and normal weight women, iii. Subcuticular and staple closure, and iv. women with&#xD;
      and without chronic medical conditions (diabetes, chronic hypertension, renal disease).&#xD;
      Interaction tests will be used to determine if the effectiveness of the skin preparation&#xD;
      methods differ across these subgroups. Tests with p &lt;0.05 will be considered statistically&#xD;
      significant. Analyses will be performed using Stata version 10.0 (Stata Corp., College&#xD;
      Station, TX).&#xD;
&#xD;
      Sample Size Estimation: The sample size estimation for the primary aim is based on an assumed&#xD;
      baseline surgical site infection rate of 8% and an anticipated clinically significant 50%&#xD;
      reduction in surgical site infection. To have 80% power to detect 50% difference in a&#xD;
      two-tailed chi-squared test with α of 0.05, a total of 1084 subjects will need to be&#xD;
      randomized. To accommodate a 10% drop out rate, 1, 192 subjects will be enrolled (596&#xD;
      chlorhexidine, 596 iodine).&#xD;
&#xD;
      SECONDARY AIM #1:&#xD;
&#xD;
      To test the hypothesis that preoperative chlorhexidine-alcohol skin preparation at cesarean&#xD;
      section significantly reduces bacterial contamination at the surgical site compared to&#xD;
      povidone-iodine Primary outcome-Proportion of subjects with surgical site skin contamination&#xD;
      after antiseptic preparation. Contamination will be defined as ≥5000 total colony-forming&#xD;
      units per milliliter on aerobic or anaerobic culture.&#xD;
&#xD;
      Secondary outcomes-Types of bacteria cultured before and after skin preparation, concordance&#xD;
      of bacteria at surgical site following preoperative skin preparation with bacteria in&#xD;
      postoperative surgical site infections.&#xD;
&#xD;
      Methods-Two skin swabs will be taken transversely across the suprapubic area, 2 finger&#xD;
      breadths above the symphysis pubis immediately before, and 5 minutes after skin preparation.&#xD;
      These swabs will be cultured under aerobic and anaerobic conditions. To ensure that the&#xD;
      groups at high risk for surgical site infections are well represented, we will ensure that&#xD;
      obese women, diabetics and women undergoing emergent cesarean deliveries are adequately&#xD;
      sample and randomized.&#xD;
&#xD;
      Statistical Analysis-Data analyses will be based on the intent-to-treat principle. The&#xD;
      primary outcome (proportion of subjects with surgical site skin contamination after skin&#xD;
      preparation) and the other categorical variables will be compared across groups using the&#xD;
      chi-squared test. Fisher's exact test will be used for variables in which expected numbers in&#xD;
      any of the cells in 2 x 2 tables is &lt;5. Tests with p &lt;0.05 will be considered significant. We&#xD;
      will also conduct stratified analysis based on the different risk groups. Finally, we will&#xD;
      calculate 95% confidence intervals around the difference in proportions and relative risk of&#xD;
      skin contamination after antiseptic skin preparation. Analyses will be performed using Stata&#xD;
      version 11.0 (Stata Corp., College Station, TX).&#xD;
&#xD;
      Sample Size Estimation-The sample size estimation for secondary aim #1 is based on the&#xD;
      primary outcome of skin contamination following skin preparation. A meta-analysis of data&#xD;
      from non-obstetric surgical procedures suggest a contamination rate of 39% after preoperative&#xD;
      skin preparation with iodine and a rate of 18% after the use of chlorhexidine [17]. On the&#xD;
      basis of an assumed contamination rate of 39% in the iodine group and 50% difference in skin&#xD;
      contamination as clinically significant, a total of 168 subjects will be needed (84&#xD;
      chlorhexidine, 84 iodine) to have 80% power in a two-tailed chi-squared test and α of 0.05.&#xD;
&#xD;
      SECONDARY AIM #2 The outcome for secondary aim#2 is attributable cost saving (if any),&#xD;
      defined as the difference in total costs between women with preoperative iodine and&#xD;
      chlorhexidine skin preparation.&#xD;
&#xD;
      Methods/Data Analysis-A cost-benefit decision analysis model will be developed depicting the&#xD;
      decision of whether to use chlorhexidine or iodine for a patient undergoing cesarean section.&#xD;
      The cost of implementing each strategy will include the purchase costs of the antiseptic&#xD;
      agents. For each antisepsis strategy, the patient would then have a probability of&#xD;
      subsequently developing surgical site infection based on results of the randomized trial&#xD;
      under the primary aim. We will calculate cost incurred by patients who did and did not&#xD;
      develop an infection.&#xD;
&#xD;
      Costs will be obtained from the Barnes-Jewish Hospital cost accounting database for the&#xD;
      surgical admission and any readmission to the hospital and office visits within 30 days after&#xD;
      cesarean section. Cost savings, if any, will be the difference between the costs in the two&#xD;
      groups. The cost-benefit analysis will be performed using TreeAge Pro 2009 (TreeAge&#xD;
      Software).&#xD;
&#xD;
      Sample Size Estimation-No formal sample size estimation is made for secondary aim #2. The&#xD;
      cost-benefit analysis will be based on outcomes among the subjects enrolled under secondary&#xD;
      aim #2.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>September 2011</start_date>
  <completion_date type="Actual">June 2015</completion_date>
  <primary_completion_date type="Actual">June 2015</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of Participants With Surgical Site Infection</measure>
    <time_frame>30 days</time_frame>
    <description>Superficial or deep surgical-site infection within 30 days after cesarean delivery, on the basis of the National Healthcare Safety Network definitions of the Centers for Disease Control and Prevention.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Length of Hospital Stay</measure>
    <time_frame>30 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Re-admissions or Office Visits for Wound-related Problems</measure>
    <time_frame>30 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Endometritis</measure>
    <time_frame>30 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Skin Irritation</measure>
    <time_frame>30 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Allergic Reaction</measure>
    <time_frame>30 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Skin Contamination After Skin Prep</measure>
    <time_frame>1 day</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cost Savings</measure>
    <time_frame>30 days</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">1147</enrollment>
  <condition>Surgical Site Infections</condition>
  <arm_group>
    <arm_group_label>Iodine-alcohol</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>8.3% povidone-iodine with 72.5% alcohol (Prevail-FX, Cardinal Health)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Chlorhexidine-alcohol</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>2% chlorhexidine gluconate with 70% alcohol (ChloraPrep, Cardinal Health)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Iodine-alcohol</intervention_name>
    <description>Skin preparation with 8.3% povidone-iodine with 72.5% alcohol (Prevail-FX, Cardinal Health) preoperative skin preparation.</description>
    <arm_group_label>Iodine-alcohol</arm_group_label>
    <other_name>Prevail-FX, Cardinal Health</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Chlorhexidine-alcohol</intervention_name>
    <description>Skin preparation with 2% chlorhexidine gluconate with 70% alcohol (ChloraPrep, Cardinal Health) preoperative skin preparation</description>
    <arm_group_label>Chlorhexidine-alcohol</arm_group_label>
    <other_name>ChloraPrep, Cardinal Health</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Women undergoing cesarean delivery at Barnes-Jewish Hospital.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Inability to obtain consent; allergy to chlorhexidine, alcohol, iodine, shellfish; and&#xD;
             evidence of infection adjacent to operative site.&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Methodius G Tuuli, MD, MPH</last_name>
    <role>Principal Investigator</role>
    <affiliation>Washington University School of Medicine</affiliation>
  </overall_official>
  <overall_official>
    <last_name>George Macones, MD, MSCE</last_name>
    <role>Study Chair</role>
    <affiliation>Washington University School of Medicine</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Barnes-Jewish Hospital</name>
      <address>
        <city>Saint Louis</city>
        <state>Missouri</state>
        <zip>63108</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.nejm.org/doi/full/10.1056/NEJMoa1511048</url>
    <description>Full text of published results</description>
  </link>
  <results_reference>
    <citation>Tuuli MG, Liu J, Stout MJ, Martin S, Cahill AG, Odibo AO, Colditz GA, Macones GA. A Randomized Trial Comparing Skin Antiseptic Agents at Cesarean Delivery. N Engl J Med. 2016 Feb 18;374(7):647-55. doi: 10.1056/NEJMoa1511048. Epub 2016 Feb 4.</citation>
    <PMID>26844840</PMID>
  </results_reference>
  <verification_date>July 2018</verification_date>
  <study_first_submitted>September 20, 2011</study_first_submitted>
  <study_first_submitted_qc>November 10, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 16, 2011</study_first_posted>
  <results_first_submitted>April 3, 2018</results_first_submitted>
  <results_first_submitted_qc>July 12, 2018</results_first_submitted_qc>
  <results_first_posted type="Actual">August 8, 2018</results_first_posted>
  <last_update_submitted>July 12, 2018</last_update_submitted>
  <last_update_submitted_qc>July 12, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">August 8, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Preoperative</keyword>
  <keyword>Antiseptics</keyword>
  <keyword>Comparative</keyword>
  <keyword>Cost</keyword>
  <keyword>Effectiveness</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Infections</mesh_term>
    <mesh_term>Surgical Wound Infection</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ethanol</mesh_term>
    <mesh_term>Chlorhexidine</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>

  <clinical_results>

    <participant_flow>
      <recruitment_details>In this single-center, randomized, controlled trial, a total of 1147 patients were enrolled from September 2011 through June 2015.</recruitment_details>
      <group_list>
        <group group_id="P1">
          <title>Chlorhexidine-alcohol</title>
          <description>2% chlorhexidine gluconate with 70% alcohol (ChloraPrep, Cardinal Health)&#xD;
Chlorhexidine-alcohol: Skin preparation with 2% chlorhexidine gluconate with 70% alcohol (ChloraPrep, Cardinal Health) preoperative skin preparation</description>
        </group>
        <group group_id="P2">
          <title>Iodine-alcohol</title>
          <description>8.3% povidone-iodine with 72.5% alcohol (Prevail-FX, Cardinal Health)&#xD;
Iodine-alcohol: Skin preparation with 8.3% povidone-iodine with 72.5% alcohol (Prevail-FX, Cardinal Health) preoperative skin preparation.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="572"/>
                <participants group_id="P2" count="575"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="572"/>
                <participants group_id="P2" count="575"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Chlorhexidine-alcohol</title>
          <description>2% chlorhexidine gluconate with 70% alcohol (ChloraPrep, Cardinal Health)&#xD;
Chlorhexidine-alcohol: Skin preparation with 2% chlorhexidine gluconate with 70% alcohol (ChloraPrep, Cardinal Health) preoperative skin preparation</description>
        </group>
        <group group_id="B2">
          <title>Iodine-alcohol</title>
          <description>8.3% povidone-iodine with 72.5% alcohol (Prevail-FX, Cardinal Health)&#xD;
Iodine-alcohol: Skin preparation with 8.3% povidone-iodine with 72.5% alcohol (Prevail-FX, Cardinal Health) preoperative skin preparation.</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="572"/>
            <count group_id="B2" value="575"/>
            <count group_id="B3" value="1147"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="28.3" spread="5.8"/>
                    <measurement group_id="B2" value="28.4" spread="5.8"/>
                    <measurement group_id="B3" value="28.4" spread="5.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="572"/>
                    <measurement group_id="B2" value="575"/>
                    <measurement group_id="B3" value="1147"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="572"/>
                    <measurement group_id="B2" value="575"/>
                    <measurement group_id="B3" value="1147"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Body mass index</title>
          <units>kg/m2</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="35.1" spread="8.9"/>
                    <measurement group_id="B2" value="34.1" spread="8.1"/>
                    <measurement group_id="B3" value="34.6" spread="8.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Scheduled cesarean</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="334"/>
                    <measurement group_id="B2" value="335"/>
                    <measurement group_id="B3" value="669"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Number of Participants With Surgical Site Infection</title>
        <description>Superficial or deep surgical-site infection within 30 days after cesarean delivery, on the basis of the National Healthcare Safety Network definitions of the Centers for Disease Control and Prevention.</description>
        <time_frame>30 days</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Chlorhexidine-alcohol</title>
            <description>2% chlorhexidine gluconate with 70% alcohol (ChloraPrep, Cardinal Health)&#xD;
Chlorhexidine-alcohol: Skin preparation with 2% chlorhexidine gluconate with 70% alcohol (ChloraPrep, Cardinal Health) preoperative skin preparation</description>
          </group>
          <group group_id="O2">
            <title>Iodine-alcohol</title>
            <description>8.3% povidone-iodine with 72.5% alcohol (Prevail-FX, Cardinal Health)&#xD;
Iodine-alcohol: Skin preparation with 8.3% povidone-iodine with 72.5% alcohol (Prevail-FX, Cardinal Health) preoperative skin preparation.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Surgical Site Infection</title>
          <description>Superficial or deep surgical-site infection within 30 days after cesarean delivery, on the basis of the National Healthcare Safety Network definitions of the Centers for Disease Control and Prevention.</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="572"/>
                <count group_id="O2" value="575"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="23"/>
                    <measurement group_id="O2" value="42"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.02</p_value>
            <method>Chi-squared</method>
            <param_type>Risk Ratio (RR)</param_type>
            <param_value>0.55</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.34</ci_lower_limit>
            <ci_upper_limit>0.90</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Length of Hospital Stay</title>
        <time_frame>30 days</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Chlorhexidine-alcohol</title>
            <description>2% chlorhexidine gluconate with 70% alcohol (ChloraPrep, Cardinal Health)&#xD;
Chlorhexidine-alcohol: Skin preparation with 2% chlorhexidine gluconate with 70% alcohol (ChloraPrep, Cardinal Health) preoperative skin preparation</description>
          </group>
          <group group_id="O2">
            <title>Iodine-alcohol</title>
            <description>8.3% povidone-iodine with 72.5% alcohol (Prevail-FX, Cardinal Health)&#xD;
Iodine-alcohol: Skin preparation with 8.3% povidone-iodine with 72.5% alcohol (Prevail-FX, Cardinal Health) preoperative skin preparation.</description>
          </group>
        </group_list>
        <measure>
          <title>Length of Hospital Stay</title>
          <units>days</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="572"/>
                <count group_id="O2" value="575"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4" lower_limit="3" upper_limit="4"/>
                    <measurement group_id="O2" value="4" lower_limit="3" upper_limit="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.24</p_value>
            <method>Wilcoxon (Mann-Whitney)</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Re-admissions or Office Visits for Wound-related Problems</title>
        <time_frame>30 days</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Chlorhexidine-alcohol</title>
            <description>2% chlorhexidine gluconate with 70% alcohol (ChloraPrep, Cardinal Health)&#xD;
Chlorhexidine-alcohol: Skin preparation with 2% chlorhexidine gluconate with 70% alcohol (ChloraPrep, Cardinal Health) preoperative skin preparation</description>
          </group>
          <group group_id="O2">
            <title>Iodine-alcohol</title>
            <description>8.3% povidone-iodine with 72.5% alcohol (Prevail-FX, Cardinal Health)&#xD;
Iodine-alcohol: Skin preparation with 8.3% povidone-iodine with 72.5% alcohol (Prevail-FX, Cardinal Health) preoperative skin preparation.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Re-admissions or Office Visits for Wound-related Problems</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="572"/>
                <count group_id="O2" value="575"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="19"/>
                    <measurement group_id="O2" value="25"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.37</p_value>
            <method>Chi-squared</method>
            <param_type>Risk Ratio (RR)</param_type>
            <param_value>0.76</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.43</ci_lower_limit>
            <ci_upper_limit>1.37</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Endometritis</title>
        <time_frame>30 days</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Chlorhexidine-alcohol</title>
            <description>2% chlorhexidine gluconate with 70% alcohol (ChloraPrep, Cardinal Health)&#xD;
Chlorhexidine-alcohol: Skin preparation with 2% chlorhexidine gluconate with 70% alcohol (ChloraPrep, Cardinal Health) preoperative skin preparation</description>
          </group>
          <group group_id="O2">
            <title>Iodine-alcohol</title>
            <description>8.3% povidone-iodine with 72.5% alcohol (Prevail-FX, Cardinal Health)&#xD;
Iodine-alcohol: Skin preparation with 8.3% povidone-iodine with 72.5% alcohol (Prevail-FX, Cardinal Health) preoperative skin preparation.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Endometritis</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="572"/>
                <count group_id="O2" value="575"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8"/>
                    <measurement group_id="O2" value="11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.49</p_value>
            <method>Chi-squared</method>
            <param_type>Risk Ratio (RR)</param_type>
            <param_value>0.73</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.30</ci_lower_limit>
            <ci_upper_limit>1.80</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Skin Irritation</title>
        <time_frame>30 days</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Chlorhexidine-alcohol</title>
            <description>2% chlorhexidine gluconate with 70% alcohol (ChloraPrep, Cardinal Health)&#xD;
Chlorhexidine-alcohol: Skin preparation with 2% chlorhexidine gluconate with 70% alcohol (ChloraPrep, Cardinal Health) preoperative skin preparation</description>
          </group>
          <group group_id="O2">
            <title>Iodine-alcohol</title>
            <description>8.3% povidone-iodine with 72.5% alcohol (Prevail-FX, Cardinal Health)&#xD;
Iodine-alcohol: Skin preparation with 8.3% povidone-iodine with 72.5% alcohol (Prevail-FX, Cardinal Health) preoperative skin preparation.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Skin Irritation</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="572"/>
                <count group_id="O2" value="575"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.08</p_value>
            <method>Fisher Exact</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Allergic Reaction</title>
        <time_frame>30 days</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Chlorhexidine-alcohol</title>
            <description>2% chlorhexidine gluconate with 70% alcohol (ChloraPrep, Cardinal Health)&#xD;
Chlorhexidine-alcohol: Skin preparation with 2% chlorhexidine gluconate with 70% alcohol (ChloraPrep, Cardinal Health) preoperative skin preparation</description>
          </group>
          <group group_id="O2">
            <title>Iodine-alcohol</title>
            <description>8.3% povidone-iodine with 72.5% alcohol (Prevail-FX, Cardinal Health)&#xD;
Iodine-alcohol: Skin preparation with 8.3% povidone-iodine with 72.5% alcohol (Prevail-FX, Cardinal Health) preoperative skin preparation.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Allergic Reaction</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="572"/>
                <count group_id="O2" value="575"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.56</p_value>
            <method>Fisher Exact</method>
            <param_type>Risk Ratio (RR)</param_type>
            <param_value>2.02</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.18</ci_lower_limit>
            <ci_upper_limit>22.11</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Skin Contamination After Skin Prep</title>
        <time_frame>1 day</time_frame>
        <population>The skin samples collected could not be processed for financial reasons.</population>
        <group_list>
          <group group_id="O1">
            <title>Chlorhexidine-alcohol</title>
            <description>2% chlorhexidine gluconate with 70% alcohol (ChloraPrep, Cardinal Health)&#xD;
Chlorhexidine-alcohol: Skin preparation with 2% chlorhexidine gluconate with 70% alcohol (ChloraPrep, Cardinal Health) preoperative skin preparation</description>
          </group>
          <group group_id="O2">
            <title>Iodine-alcohol</title>
            <description>8.3% povidone-iodine with 72.5% alcohol (Prevail-FX, Cardinal Health)&#xD;
Iodine-alcohol: Skin preparation with 8.3% povidone-iodine with 72.5% alcohol (Prevail-FX, Cardinal Health) preoperative skin preparation.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Skin Contamination After Skin Prep</title>
          <population>The skin samples collected could not be processed for financial reasons.</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="00000"/>
                <count group_id="O2" value="00000"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Cost Savings</title>
        <time_frame>30 days</time_frame>
        <population>Cost data was not collected because it as not logistically feasible.</population>
        <group_list>
          <group group_id="O1">
            <title>Chlorhexidine-alcohol</title>
            <description>2% chlorhexidine gluconate with 70% alcohol (ChloraPrep, Cardinal Health)&#xD;
Chlorhexidine-alcohol: Skin preparation with 2% chlorhexidine gluconate with 70% alcohol (ChloraPrep, Cardinal Health) preoperative skin preparation</description>
          </group>
          <group group_id="O2">
            <title>Iodine-alcohol</title>
            <description>8.3% povidone-iodine with 72.5% alcohol (Prevail-FX, Cardinal Health)&#xD;
Iodine-alcohol: Skin preparation with 8.3% povidone-iodine with 72.5% alcohol (Prevail-FX, Cardinal Health) preoperative skin preparation.</description>
          </group>
        </group_list>
        <measure>
          <title>Cost Savings</title>
          <population>Cost data was not collected because it as not logistically feasible.</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="00000"/>
                <count group_id="O2" value="00000"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>30 days</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Chlorhexidine-alcohol</title>
          <description>2% chlorhexidine gluconate with 70% alcohol (ChloraPrep, Cardinal Health)&#xD;
Chlorhexidine-alcohol: Skin preparation with 2% chlorhexidine gluconate with 70% alcohol (ChloraPrep, Cardinal Health) preoperative skin preparation</description>
        </group>
        <group group_id="E2">
          <title>Iodine-alcohol</title>
          <description>8.3% povidone-iodine with 72.5% alcohol (Prevail-FX, Cardinal Health)&#xD;
Iodine-alcohol: Skin preparation with 8.3% povidone-iodine with 72.5% alcohol (Prevail-FX, Cardinal Health) preoperative skin preparation.</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="572"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="575"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="572"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="575"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="15" subjects_at_risk="572"/>
                <counts group_id="E2" subjects_affected="15" subjects_at_risk="575"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Adverse skin reactions</sub_title>
                <description>Adverse skin reactions including erythema, skin irritation and allergic skin reactions.</description>
                <counts group_id="E1" events="15" subjects_affected="15" subjects_at_risk="572"/>
                <counts group_id="E2" events="15" subjects_affected="15" subjects_at_risk="575"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Methodius Tuuli</name_or_title>
      <organization>Washington University</organization>
      <phone>6785582874</phone>
      <email>methodiustuuli@yahoo.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

